Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Target Price
The average target price of CABA is 14 and suggests 452% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell